DDInter1628 DDInter899
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
Ruxolitinib {u} (Compound) binds {v} (Gene) RPS6KA6
Ruxolitinib {u} (Compound) upregulates {v} (Gene) FOXJ3
Ruxolitinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Ruxolitinib {u} (Compound) downregulates {v} (Gene) AKT1
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Anaemia
Ruxolitinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) DYRK1A
Ruxolitinib (Compound) treats hematologic cancer (Disease)
Ruxolitinib (Compound) binds RPS6KA6 (Gene)
Ruxolitinib (Compound) upregulates FOXJ3 (Gene)
Ruxolitinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Ruxolitinib (Compound) downregulates AKT1 (Gene)
Ruxolitinib (Compound) causes Anaemia (Side Effect)
Ruxolitinib (Compound) binds DYRK1A (Gene) and Ruxolitinib (Compound) upregulates DYRK1A (Gene)